Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01135446 · ClinicalTrials.gov registry record · Phase 1
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01135446 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 35 participants.
The verdict
NCT01135446, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single oral doses of 0.001 mg to 2.5 mg dapagliflozin in healthy subjects.
Interventions
- DRUG dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01135446
The ClinicalTrials.gov registry entry for NCT01135446 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dapagliflozin is the first listed.
NCT01135446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01135446 about?
NCT01135446 is a clinical study titled "Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects". The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single oral doses of 0.001 mg to 2.5 mg dapagliflozin in healthy subjects.
What is the current status of trial NCT01135446?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2010-05. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01135446?
The interventions under investigation include: dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT01135446?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.